Quote this publication Share Print

AVASTIN (bevacizumab), monoclonal antibody

ONCOLOGY - New indication
Opinions on drugs - Posted on Jan 18 2016

Reason for request

Extension of Inclusion

No clinical added value demonstrated in treatment of the first recurrence of platinum-sensitive ovarian cancer or the recurrence of platinum-resistant ovarian cancer.

  • AVASTIN has Marketing Authorisation :

- in combination with carboplatin and gemcitabine, in the treatment of the first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer ;

in combination with paclitaxel, with topotecan or with pegylated liposomal doxorubicin, in the case of recurrence of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

  • The addition of bevacizumab to the chemotherapy has been shown to have a moderate effect on progression-free survival, without a demonstrated increase in overall survival and quality of life but with an increase in toxicity, particularly vascular toxicity.




Clinical Benefit

Substantial

-


Clinical Added Value

no clinical added value

-


Therapeutic use

-

Contact Us

Évaluation des médicaments